Fractyl Health (NASDAQ:GUTS) Director Buys $49,999.89 in Stock

Fractyl Health, Inc. (NASDAQ:GUTS) Director William Bradley bought 68,493 shares of Fractyl Health stock in a transaction that occurred on Wednesday, June 10th. The stock was purchased at an average price of $0.73 per share, with a total value of $49,999.89. Following the purchase, the director directly owned 84,622 shares in the company, valued at $61,774.06. The trade was a 424.66% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Fractyl Health Stock Performance

GUTS stock traded down $0.01 during midday trading on Thursday, reaching $0.72. The stock had a trading volume of 605,424 shares, compared to its average volume of 3,974,397. The stock has a market cap of $114.85 million, a PE ratio of -0.56 and a beta of 2.34. The company has a debt-to-equity ratio of 1.41, a quick ratio of 4.28 and a current ratio of 4.28. The firm has a fifty day simple moving average of $0.68 and a two-hundred day simple moving average of $1.08. Fractyl Health, Inc. has a 52-week low of $0.38 and a 52-week high of $2.45.

Fractyl Health (NASDAQ:GUTS) last issued its earnings results on Tuesday, May 12th. The company reported $0.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.23. As a group, equities research analysts anticipate that Fractyl Health, Inc. will post -0.6 EPS for the current year.

Institutional Investors Weigh In On Fractyl Health

Institutional investors have recently bought and sold shares of the company. Rosalind Advisors Inc. acquired a new stake in Fractyl Health in the 3rd quarter worth about $7,950,000. CM Management LLC acquired a new stake in Fractyl Health in the 3rd quarter worth about $954,000. GSA Capital Partners LLP acquired a new stake in Fractyl Health in the 3rd quarter worth about $285,000. Accredited Investors Inc. acquired a new stake in Fractyl Health in the 1st quarter worth about $46,000. Finally, Catalio Capital Management LP boosted its holdings in Fractyl Health by 5.3% in the 4th quarter. Catalio Capital Management LP now owns 5,491,866 shares of the company’s stock worth $12,082,000 after buying an additional 277,630 shares during the last quarter.

Analyst Ratings Changes

A number of research firms have weighed in on GUTS. Wall Street Zen upgraded Fractyl Health from a “strong sell” rating to a “hold” rating in a research note on Saturday, May 16th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Fractyl Health in a research note on Tuesday, May 12th. Canaccord Genuity Group reiterated a “buy” rating and set a $8.00 price objective on shares of Fractyl Health in a research note on Thursday, March 26th. Finally, HC Wainwright reiterated a “buy” rating and set a $8.00 price objective on shares of Fractyl Health in a research note on Thursday, June 4th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $5.40.

About Fractyl Health

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.